 Prostate cancer is the most common cancer diagnosed and the second most common cause of cancer death in men in North America Jemal 2003. Many patients with localized disease have an excellent long-term survival and high cure rates with standard approaches DAmico 1998. However, patients with high risk, locally advanced and metastatic disease have a poor prognosis, and although hormonal therapy in the form of medical or surgical castration can induce significant long-term remissions,development of androgen independent disease is inevitable. Androgen independent AI disease, also termed hormone refractory prostate cancer HRPC, is clinically detected by a rise in prostate specific antigen PSA and worsening of symptoms. Once patients reach this stage, therapeutic options are limited and prognosis is poor 